Negative operating cash flow

Hong Kong IPO disclosure precedents · 164 companies, 164 items

net cash used in operating activities in a period, reasons and measures

2026-06-23Prospectus
Anker Innovations Technology Co., Ltd.安克创新科技股份有限公司00668.HK

For the three months ended March 31, 2026, our net cash used in operating activities was RMB450.6 million, which was primarily attributable to profit before taxation of RMB558.7 million, partially offset by tax paid of RMB141.2 million, adjusted for certain non-cash and non-operating items, including (i) increase in inventories from RMB4,997.1 million as of December 31, 2025 to RMB5,568.9 million as of March 31, 2026 and (ii) a decrease in contract liabilities from RMB552.5 million as of December 31, 2025 to RMB335.4 million as of March 31, 2026.

Financial Information · p. 239
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-22Prospectus
Zhejiang Laifual Drive Co., Ltd.浙江来福谐波传动股份有限公司03952.HK

We recorded net cash used in operating activities of RMB35.2 million, RMB33.7 million and RMB63.4 million in 2023, 2024 and 2025, respectively.

Business · p. 166

Against the background of long cash conversion cycle and the mismatch of the cash receipts from trade receivables and payments for trade payables during the Track Record Period, we recorded net operating cash outflows throughout the Track Record Period.

Financial Information · p. 236

Going forward, we will continue to implement inventory management measures to enhance inventory turnover and working capital status.

Financial Information · p. 236
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-18Application Proof
Guangzhou Zhiyi Biotechnology Co., Ltd.广州知易生物科技股份有限公司

During the Track Record Period, we recorded net cash used in operating activities of RMB45.0 million in 2024 and RMB22.7 million in 2025.

Financial Information · p. 237

To fund our operations, we have relied primarily on equity financing from investors.

Financial Information · p. 237

In 2024, we completed Series C financing rounds, receiving RMB77.0 million in capital contributions by investors, which significantly strengthened our cash position.

Financial Information · p. 237
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-17Prospectus

As the MGR Group is currently in its development phase, it has negative operating and investing cash flows, while financing cash flows are positive.

Financial Information · p. 257

This is due to the limited revenue generated by the MGR Group from mining equipment rentals and the high capital expenditure required to complete the construction of mining infrastructure and processing facilities.

Financial Information · p. 257

Net cash flows used in operating activities | (16,489) | (6,281) | (21,714)

Financial Information · p. 258
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-15Application Proof
TRIAPEX LABORATORIES CO., LTD.江苏鼎泰药物研究(集团)股份有限公司

Our net cash used in operating activities in the years ended December 31, 2023, 2024 and 2025 was primarily attributable to our continued investment in building up our NHPs for breeding and the impact of market conditions on our nonclinical study service business.

Summary · p. 10

Excluding cash payments for NHPs for breeding, we recorded net cash generated from operating activities in each period.

Summary · p. 10
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-15Prospectus
Shaanxi Micot Pharmaceutical Technology Co., Ltd.陕西麦科奥特医药科技股份有限公司02335.HK

We recorded net cash used in operating activities of RMB107.7 million and RMB137.1 million for 2024 and 2025, respectively.

Financial Information · p. 262

During the Track Record Period and up to the Latest Practicable Date, we had financed our operations primarily through equity and debt financing and we had not experienced any difficulty in obtaining such financing.

Financial Information · p. 262
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-15Application Proof
Lynk Pharmaceuticals Co., Ltd.凌科药业(浙江)股份有限公司

During the Track Record Period, we funded our working capital requirements through equity financing.

Financial Information · p. 230

While we had net operating cash outflows during the Track Record Period, we believe our liquidity requirements will be satisfied by using funds from a combination of our cash and cash equivalents, net [REDACTED] from the [REDACTED] and other funds raised from the capital markets from time to time.

Financial Information · p. 230
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-15Prospectus
Shanghai Seer Intelligent Technology Co., Ltd.上海仙工智能科技股份有限公司06106.HK

We recorded a net loss and had net operating cash outflows during the Track Record Period.

Financial Information · p. 240

In 2024, we incurred net cash outflows in operating activities primarily due to a rapid growth in our trade receivables as a result of our enlarged business scale.

Financial Information · p. 248

We plan to adopt an incentive mechanism that links sales team’s performance-based bonuses directly to their collections of trade receivables.

Financial Information · p. 240
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-12Application Proof
Yantai Lannacheng Biotechnology Co., Ltd.烟台蓝纳成生物技术股份有限公司

We recorded net cash flows used in operating activities of RMB132.0 million and RMB143.3 million in 2024 and 2025, respectively.

Financial Information · p. 272

During the Track Record Period, we primarily funded our working capital requirements through equity financing.

Financial Information · p. 272

Our Directors are of the opinion that, taking into account the financial resources available to us, including cash and cash equivalents of RMB188.5 million as of April 30, 2026 and the estimated [REDACTED] from the [REDACTED], and considering our cash burn rate, we have available sufficient working capital to cover at least 125% of our costs, including research and development costs, administrative expenses, and other operating costs, for at least the next 12 months from the date of this document.

Financial Information · p. 274
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-05-29Application Proof
Shanghai GoNa Semiconductor Technology Co., Ltd.上海果纳半导体技术股份有限公司

We have historically financed our operations primarily through a consolidation of cash flow generated from our operations, proceeds from Pre-[REDACTED] Investments, and interest-bearing borrowings.

Financial Information · p. 225

Net cash flows (used in)/generated from operating activities | (76,329) | (25,340) | 1,024

Financial Information · p. 225
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-05-29Application Proof
Megatronix Inc.镁佳股份有限公司

We experienced negative operating cash flows during the Track Record Period.

Financial Information · p. 221

Based on our available cash and cash equivalents, and despite the net operating cash outflows during the Track Record Period, we believe our cash balance is sufficient to meet our operating needs and support our planned expansion.

Financial Information · p. 221

Our accumulated deficit as of January 1, 2023, as well as net losses, adjusted net losses (non-IFRS measures), and net operating cash outflows during the Track Record Period primarily reflect these deliberate early-stage commitments.

Summary · p. 11
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-05-29Application Proof
Wuxi Autolink Intelligence Tech Co., Ltd.无锡车联天下智能科技股份有限公司

We had negative operating cash flow of RMB697.0 million, RMB1,011.1 million and RMB872.2 million in 2023, 2024 and 2025, respectively.

Financial Information · p. 259

Taking into account the financial resources available to us, including our cash and cash equivalents on hand, unutilized bank facilities, internally generated funds and the estimated [REDACTED] from the [REDACTED], our Directors are of the view that we have sufficient working capital to meet our present needs and for the next 12 months from the date of this document.

Financial Information · p. 259
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-05-29Application Proof
Zhejiang Zentel Memory Technology Co., Ltd.浙江力积存储科技股份有限公司

We recorded net cash outflows from operating activities in 2023, 2024 and 2025, amounting to RMB62.9 million, RMB18.2 million and RMB192.1 million, respectively, mainly due to our loss before tax amounting to RMB245.2 million, RMB109.8 million and RMB11.1 million in the respective years.

Summary · p. 7

We plan to improve our net operating cash outflows position by (i) enhancing inventory management, and (ii) optimizing our receivables and payables.

Summary · p. 7
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-05-28Prospectus
LongBio Pharma (Suzhou) Co., Ltd.天辰生物医药(苏州)股份有限公司01779.HK

We recorded net cash flows used in operating activities of RMB104.1 million and RMB121.0 million for the years ended December 31, 2024 and 2025, respectively.

Financial Information · p. 241

During the Track Record Period and up to the Latest Practicable Date, we have primarily funded our working capital requirements through equity financing and debt financing.

Financial Information · p. 241
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-05-28Application Proof
Lupeng Pharmaceutical Ltd.麓鹏制药有限公司

During the Track Record Period, we incurred negative cash flows from our operations and substantially all of our operating cash outflows resulted from our R&D and administrative activities.

Financial Information · p. 238

We expect to generate more cash flow from our operating activities through the launch and commercialization of our products, enhanced cost containment capacity and operating efficiency, as well as potentially from collaboration and/or licensing arrangements.

Financial Information · p. 238
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-05-28Application Proof
Yangzhou Nanopore Innovative Materials Technology Co., Ltd.扬州纳力新材料科技股份有限公司

In 2023, 2024 and 2025, we recorded net cash used in operating activities of RMB164.8 million, RMB338.2 million and RMB297.1 million, respectively.

Business · p. 162

Together with our loss-making operations, these factors contributed to our net cash used in operating activities during the Track Record Period.

Business · p. 158

Going forward, we plan to strengthen customer credit assessment, payment tracking and collection procedures, improve inventory planning based on production schedules and sales forecasts and manage procurement, prepayments and deposits based on actual production and project needs.

Business · p. 162
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-05-28Application Proof
Suzhou Calmcar Electronics Technology Co., Limited苏州天瞳威视电子科技股份有限公司

(iii) notwithstanding the operating losses and net cash operating outflows during the years ended December 31, 2023, 2024 and 2025, the expected commercialization and revenue growth prospects did not indicate impairment

Financial Information · p. 199

However, we expect our net operating cash flow to turn positive in 2026, primarily driven by the collection of a substantial portion of our outstanding trade receivables, resulting in an overall improvement in our cash flow position.

Summary · p. 16
The company's explanation, the adviser's view and the page in the filing: see Matters

Tell us